<span id="midArticle_start"/>May 31 Novartis AG
<span id="midArticle_0"/>* Novartis says combination of Tafinlar and Mekinist showssignificant survival benefit in patients with metastaticmelanoma
<span id="midArticle_1"/> <span class="first-article-divide"/>* Say three-year data from Phase I-II study reinforcelong-term overall survival benefit of combination therapy
<span id="midArticle_2"/> <span class="second-article-divide"/> <span class="third-article-divide"/>* Say results to be presented at the Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) Further company coverage: (Reporting By Zurich Slot)
<span id="midArticle_3"/>
<span id="midArticle_0"/>* Novartis says combination of Tafinlar and Mekinist showssignificant survival benefit in patients with metastaticmelanoma
<span id="midArticle_1"/> <span class="first-article-divide"/>* Say three-year data from Phase I-II study reinforcelong-term overall survival benefit of combination therapy
<span id="midArticle_2"/> <span class="second-article-divide"/> <span class="third-article-divide"/>* Say results to be presented at the Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) Further company coverage: (Reporting By Zurich Slot)
<span id="midArticle_3"/>
via Smart Health Shop Forum http://ift.tt/1HEBpTW
No comments:
Post a Comment